Key clinical point: Pretransplant induction therapy with bortezomib, lenalidomide, and dexamethasone deepened responses in patients with newly diagnosed multiple myeloma.

Major finding: After six cycles of induction, the complete response rate was 33.4%, with a rate of undetectable minimal residual disease of 28.8%.

Study details: An interim analysis from the phase 3 PETHEMA/GEM2012 study.

Disclosures: The study was supported by Celgene, Janssen, Pierre Fabré, and the Instituto de Salud Carlos III. The authors reported financial affiliations with Celgene, Janssen, and several other companies.